STAT+: Eli Lilly’s experimental diabetes drug reduced weight and blood sugar in clinical trial

Eli Lilly said Thursday that a study showed its experimental diabetes drug, tirzepatide, reduced patients’ blood sugar and body weight more than a rival medicine, Novo Nordisk’s Ozempic.

Investors had been nervously awaiting the result, which was reported in a press release.

Continue to STAT+ to read the full story…

STAT+: Eli Lilly’s experimental diabetes drug reduced weight and blood sugar in clinical trial

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top